

## Title (en)

BIODEGRADABLE VEHICLES AND DELIVERY SYSTEMS OF BIOLOGICALLY ACTIVE SUBSTANCES

## Title (de)

BIOLOGISCH ABBAUBARES TRÄGER-MATERIAL SOWIE ABGABESYSTEME FÜR BIOLOGISCH AKTIVE SUBSTANZEN

## Title (fr)

VEHICULES BIODEGRADABLES ET SYSTEMES D'ADMINISTRATION DE SUBSTANCES BIOLOGIQUEMENT ACTIVES

## Publication

**EP 1299048 A4 20050928 (EN)**

## Application

**EP 01918249 A 20010226**

## Priority

- CN 00120871 A 20000803
- IN 694MU2000 A 20000725
- US 0106138 W 20010226
- US 60566100 A 20000628

## Abstract (en)

[origin: WO0200137A1] Biodegradable vehicle and delivery systems of physiologically, pharmacologically and biologically active substance(s) (BAS) are provided. The biodegradable vehicles may be prepared by blending biodegradable polymers and plasticizers using a novel solvent evaporation method. This method involves dissolving the biodegradable polymer or copolymer and a plasticizer or mixtures of plasticizers into a volatile solvent or mixtures of volatile solvents. The volatile solvent is then removed using vacuum or at an elevated temperature or using a combination of both vacuum and elevated temperature. The biodegradable vehicle can be used as filler or spacer in the body. Biologically active substances (BAS) can be added to the biodegradable vehicle at any step during or after preparing the biodegradable vehicle, or just prior to using the biodegradable delivery system. This biodegradable delivery system provides controlled release of the BAS over the desired period of time. The biodegradable vehicle or BAS-loaded biodegradable delivery system can be injected, implanted, smeared or applied in vivo in an animal, bird or human.

## IPC 1-7

**A61K 9/06**; **A61K 47/34**; **A61K 47/14**; **A61K 47/22**; **A61K 31/00**; **A61K 38/00**; **A61L 27/00**

## IPC 8 full level

**A61K 47/30** (2006.01); **A61F 2/00** (2006.01); **A61F 13/00** (2006.01); **A61K 9/00** (2006.01); **A61K 9/06** (2006.01); **A61K 9/08** (2006.01); **A61K 9/16** (2006.01); **A61K 9/22** (2006.01); **A61K 31/00** (2006.01); **A61K 38/00** (2006.01); **A61K 47/08** (2006.01); **A61K 47/10** (2006.01); **A61K 47/14** (2006.01); **A61K 47/16** (2006.01); **A61K 47/32** (2006.01); **A61K 47/34** (2006.01); **A61K 47/42** (2006.01); **A61L 27/00** (2006.01); **A61L 31/04** (2006.01); **A61L 31/14** (2006.01); **A61L 31/16** (2006.01); **C08L 101/16** (2006.01); **A61K 47/22** (2006.01)

## CPC (source: EP)

**A61K 9/0019** (2013.01); **A61K 9/0024** (2013.01); **A61K 9/1647** (2013.01); **A61K 9/1694** (2013.01); **A61K 31/00** (2013.01); **A61K 47/34** (2013.01); **A61L 31/041** (2013.01); **A61L 31/141** (2013.01); **A61L 31/148** (2013.01); **A61L 31/16** (2013.01); **C08K 5/11** (2013.01); **A61K 9/06** (2013.01); **A61K 47/10** (2013.01); **A61K 47/14** (2013.01); **A61K 47/22** (2013.01); **A61L 2300/602** (2013.01)

## Citation (search report)

- [X] EP 0537559 A1 19930421 - ATRIX LAB INC [US]
- [X] WO 9947073 A1 19990923 - MERCK & CO INC [US], et al
- [X] WO 9827963 A2 19980702 - ALZA CORP [US], et al
- [X] WO 9827962 A2 19980702 - ALZA CORP [US], et al
- [X] US 5447725 A 19950905 - DAMANI NALINKANT C [US], et al
- [X] WO 0024374 A1 20000504 - ATRIX LAB INC [US], et al
- [X] WO 9848859 A1 19981105 - GUILFORD PHARM INC [US], et al
- [X] SHAH N H ET AL: "A BIODEGRADABLE INJECTABLE IMPLANT FOR DELIVERING MICRO AND MACROMOLECULES USING POLY(LACTIC-CO-GLYCOLIC) ACID (PLGA) COPOLYMERS", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 27, no. 2, 1 November 1993 (1993-11-01), pages 139 - 147, XP000400402, ISSN: 0168-3659
- [X] SINGH U V ET AL: "REDUCED TOXICITY AND ENHANCED ANTITUMOR EFFICACY OF PLUMBAGIN USING POLY (LACTIC-CO-GLYCOLIC) BIODEGRADABLE INJECTABLE IMPLANT", INDIAN JOURNAL OF PHARMACOLOGY, vol. 29, no. 3, 1997, pages 168 - 172, XP001070322, ISSN: 0253-7613
- [X] GRAHAM P D ET AL: "Phase inversion dynamics of PLGA solutions related to drug delivery", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 58, no. 2, 29 March 1999 (1999-03-29), pages 233 - 245, XP004164095, ISSN: 0168-3659
- [X] SHIVELY M L ET AL: "Physico-chemical characterization of a polymeric injectable implant delivery system", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 33, no. 2, February 1995 (1995-02-01), pages 237 - 243, XP004037626, ISSN: 0168-3659
- [X] RADOMSKY M L ET AL: "The controlled release of ganirelix from the ATRIGEL(TM) injectable implant system", PROCEEDINGS OF THE CONTROLLED RELEASE SOCIETY 1993 UNITED STATES, no. 20, 1993, pages 458 - 459, XP009051801
- [X] JARR EM ET AL: "Sustained release of lidocaine from an injectable implant system for treatment of post-operative pain", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, vol. 26, July 1999 (1999-07-01), pages 631 - 632, XP002133945, ISSN: 1022-0178
- See references of WO 0200137A1

## Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

## DOCDB simple family (publication)

**WO 0200137 A1 20020103**; AU 4534601 A 20020108; CA 2413157 A1 20020103; CN 1283215 C 20061108; CN 1438858 A 20030827; EP 1299048 A1 20030409; EP 1299048 A4 20050928; JP 2004511431 A 20040415; NZ 523385 A 20050930

## DOCDB simple family (application)

**US 0106138 W 20010226**; AU 4534601 A 20010226; CA 2413157 A 20010226; CN 01811851 A 20010226; EP 01918249 A 20010226; JP 2002504922 A 20010226; NZ 52338501 A 20010226